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Abstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic 
cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and 
in combination have yielded disappointing results, spurring the ongoing search for new agents 
and combinations in this aggressive malignancy. Inhibitors of the epidermal growth factor 
receptor (EGFR) have shown promising activity in multiple solid tumors types, and preclini-
cal data support a role for EGFR inhibition in pancreatic cancer. A recent phase III study by 
the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) demonstrated a 
signiﬁ  cant survival beneﬁ  t with the addition of the EGFR tyrosine kinase inhibitor, erlotinib, 
to gemcitabine chemotherapy for the ﬁ  rst-line treatment of patients with advanced pancreatic 
cancer, becoming the ﬁ  rst phase III study to demonstrate a survival beneﬁ  t of combination therapy 
as well as targeted therapy in this disease. This article reviews the evidence supporting EGFR 
inhibition and the use of erlotinib in advanced pancreatic cancer as well as future implications 
of targeted therapy in this challenging malignancy.
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Introduction
Pancreatic carcinoma is the fourth leading cause of cancer death in the United States 
with 37,170 new cases and 33,370 deaths anticipated in 2007. More than half of patients 
have metastatic disease at the time of diagnosis, with a median 5-year survival of 2%. 
Locally advanced, unresectable disease likewise accounts for over 25% of patients 
at the time of presentation and confers a median 5-year survival of 8% (Jemal et al 
2007). Locally advanced tumors together with metastatic disease are often collec-
tively considered as advanced pancreatic cancer for the purposes of clinical research, 
although there are subtle differences in prognosis (making stratiﬁ  cation in such studies 
a necessity) as well as in treatment options for each.
Current standards of care for advanced pancreatic cancer have evolved from a 
1997 study by Burris et al that resulted in approval of gemcitabine for the treatment of 
this disease (Burris et al 1997). This study demonstrated a clinical beneﬁ  t response as 
well as a modest survival beneﬁ  t with the use of gemcitabine compared to ﬂ  uorouracil 
(5-FU) monotherapy. Clinical beneﬁ  t response was deﬁ  ned as a sustained improvement 
in pain, Karnofsky performance status, or weight for at least 4 weeks on therapy. In 
patients treated with gemcitabine, clinical beneﬁ  t response was achieved in 23.8% of 
patients, versus 4.8% of those treated with 5-FU (p = 0.0022). Median survival dura-
tions were 5.65 months versus 4.41 months in the gemcitabine versus 5-FU groups, 
respectively (p = 0.0025).
Multiple ensuing studies have evaluated gemcitabine in combination with other 
cytotoxic agents for treatment of advanced pancreatic cancer. Over the past decade, 
a number of large, randomized phase III trials have failed to demonstrate a survival 
advantage for any gemcitabine-containing combination, including gemcitabine plus Biologics: Targets & Therapy 2008:2(1) 84
Kelley and Ko
ﬂ  uoropyrimidines, platinum analogues, and topoisomerase 
inhibitors (Berlin et al 2002; Rocha Lima et al 2004; Louvet 
et al 2005; Abou-Alfa et al 2006; Herrmann et al 2007), 
although a recent pooled analysis did suggest a survival 
beneﬁ  t for the combination of gemcitabine and a platinum 
analogue (Heinemann et al 2007). One positive phase III 
study was reported in Europe in 2005 with the combination 
of gemcitabine and capecitabine, but these data have yet to 
be presented in mature form (Cunningham et al 2005). In 
2006, a Cochrane review of data from 50 trials concluded that 
combination cytotoxic chemotherapy did not improve overall 
survival beyond monotherapy (Yip et al 2006). Conversely, 
a recent meta-analysis of 15 randomized trials suggests there 
may be a small but signiﬁ  cant survival beneﬁ  t of gemcitabine-
based combination therapy, with greatest beneﬁ  t in patients 
with good performance status (Heinemann et al 2007).
Given the modest survival beneﬁ  ts of traditional chemo-
therapy, the search for new active agents in this aggressive 
malignancy is an area of avid investigation. In addition 
to cytotoxic chemotherapy, multiple targeted agents have 
been and are being studied for efﬁ  cacy in pancreatic cancer. 
Agents that have been rigorously evaluated in phase III study 
designs include matrix metalloproteinase inhibitors, farnesyl 
transferase inhibitors, angiogenesis inhibitors, and inhibitors 
of the epidermal growth factor receptor (EGFR), with myriad 
other targeted therapies under active investigation in earlier 
phases of testing.
Preclinical studies show that EGFR-mediated signaling 
is involved in tumorigenesis of pancreatic cancer. Erlotinib 
(OSI-774, Tarceva®; OSI Pharmaceuticals, Melville, NY, in 
collaboration with Genentech and Roche Pharmaceuticals) is 
a small molecule tyrosine kinase inhibitor (TKI) with speci-
ﬁ  city for EGFR. Based on the ﬁ  ndings of preclinical studies 
and early phase clinical trials, the National Cancer Institute 
of Canada Clinical Trials Group (NCIC-CTG) conducted a 
phase III study (PA.3) comparing single-agent gemcitabine 
to gemcitabine in combination with erlotinib as ﬁ  rst-line 
therapy for advanced pancreatic cancer. The PA.3 study 
became the ﬁ  rst phase III randomized study to demonstrate 
a signiﬁ  cant survival beneﬁ  t with combination therapy as 
well as with a targeted agent in advanced pancreatic cancer 
(Moore et al 2005). On this basis, the FDA approved erlotinib 
in combination with gemcitabine chemotherapy for ﬁ  rst-line 
use in locally advanced and metastatic pancreatic carcinoma 
in 2005. This article will review the molecular mechanism of 
EGFR inhibition as a therapeutic approach in solid tumors; 
the preclinical data supporting EGFR inhibition in solid 
tumors including pancreatic cancer; and ﬁ  nally, the clinical 
trials that have established the small molecule TKI erlotinib 
as an approved therapy for advanced pancreatic cancer.
EGF receptor: structure, function, 
and transforming potential
The EGF receptor is a ubiquitous 170-kd transmembrane 
glycoprotein in the HER (erbB) family of receptors (Arteaga 
2001; Yarden and Sliwkowski 2001; Grunwald and Hidalgo 
2003; Kolb et al 2006; Cohenuram and Saif 2007). Also 
known as HER-1 or erbB1, this receptor includes an 
N-terminal extracellular ligand-binding domain, a transmem-
brane region, and an intracellular domain with tyrosine kinase 
function and C-terminal regulatory motifs. The extracellular 
ligand-binding domain binds speciﬁ  c ligands including EGF, 
transforming growth factor alpha (TGFα), heparin-binding 
growth factor, amphiregulin, betacellulin, and epiregulin. 
The existence of multiple ligands may confer redundancy in 
activation of EGFR signaling as well as enable differential 
signaling patterns speciﬁ  c to each ligand.
Upon ligand binding, the EGFR undergoes homodimer-
ization or heterodimerization. Coreceptors in heterodimer 
formation include the other members of the HER family 
of receptors: HER2/neu, HER3, and HER4 (Arteaga 2001; 
Yarden and Sliwkowski 2001; Grunwald and Hidalgo 2003). 
Dimerization results in autophosphorylation of EGFR 
C-terminal regulatory motifs and subsequent activation 
of downstream signaling. Multiple combinatorial receptor 
interactions may inﬂ  uence the speciﬁ  city and potency of 
EGFR-mediated signal transduction. EGFR activation has 
been shown to activate multiple downstream signal transduc-
tion pathways including the Ras-Raf-MAPK and PI3K/Akt 
pathways, thereby inﬂ  uencing cell cycle progression, angio-
genesis, growth, and survival.
In the context of this role in regulation of cell proliferation, 
EGFR signaling pathways have been linked to the pathogenesis 
of multiple human malignancies. In tissue culture, overex-
pression of members of the EGFR family as well as activa-
tion of EGFR signaling can cause malignant transformation 
(Grunwald and Hidalgo 2003). EGFR may be overexpressed 
in malignant tumor specimens arising from the upper aerodi-
gestive tract, pancreas, colon, rectum, breast, ovary, bladder, 
kidney, prostate, and central nervous system (Grandis and Sok 
2004). This overexpression may occur by gene ampliﬁ  cation 
or by upregulation of autocrine and paracrine growth factors 
that subsequently induce EGFR expression.
In addition to elevated transcript and/or protein levels of 
EGFR, activating mutations within the EGFR gene have also 
been implicated in several malignancies. In non-small-cell lung Biologics: Targets & Therapy 2008:2(1) 85
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cancers (NSCLC), activating mutations have been identiﬁ  ed 
within exons 18-21 of the tyrosine kinase domain (Grunwald 
and Hidalgo 2003; Paez et al 2004; Lynch et al 2004; Pao and 
Miller 2005; Takano et al 2005). Mutations in the N-terminal 
extracellular ligand binding domain including the EGFRvIII 
variant are found in gliomas (Pao and Miller 2005). However, 
no activating mutations have been identiﬁ  ed in pancreatic 
cancer to date (Kwak et al 2006; Lee et al 2007; Tzeng et al 
2007a). Other potential mechanisms of inappropriate EGFR 
activation include ligand overexpression, coreceptor over-
expression or mutations leading to altered dimerization, and 
abnormalities in regulatory mechanisms including receptor 
internalization, degradation, and recycling.
Blockade of the EGFR pathway by various strategies 
has been shown to inhibit proliferation of tumor cell lines in 
vitro, leading to clinical trials of EGFR inhibitors in a wide 
array of human malignancies. A therapeutic role has now 
been established for EGFR inhibitors in carcinomas of the 
head and neck, lung, breast, and colon. With the approval 
of erlotinib for treatment of pancreatic cancer in 2005, 
EGFR inhibition has now become an appropriate strategy 
for pancreatic cancer as well.
Mechanisms of pharmacologic 
EGFR inhibition
Two principal mechanisms of therapeutic EGFR inhibition 
have been developed: monoclonal antibodies (mAbs) that bind 
to the extracellular domain of EGFR, and TKIs that inhibit the 
intracellular tyrosine kinase domain. MAbs, by blocking ligand 
binding to the receptor, interfere with dimerization, phosphory-
lation, and signal transduction. Antibody binding can also cause 
receptor endocytosis and downregulation from the cell surface 
(Arteaga 2001; Grunwald and Hidalgo 2003; Marshall 2006). 
Additionally, bound antibody may recruit Fc receptor effector 
cells leading to antibody-dependent cell-mediated cytotoxicity 
(Arteaga 2001). In contrast, TKIs, by competitively binding 
to the ATP binding site of the intracellular domain of EGFR, 
inhibit EGFR autophosphorylation and impair downstream 
signaling, leading to cell cycle arrest and apoptosis in vitro 
(Moyer et al 1997; Pollack et al 1999; Arteaga 2001; Grunwald 
and Hidalgo 2003; Pao and Miller JCO 2005; Marshall 2006). 
In addition to these two major classes of agents, other strate-
gies targeting the epidermal growth factor (EGF) pathway are 
in preclinical and early clinical phases of development. These 
include immunotoxin conjugates, antisense oligonucleotides, 
and agents that target downstream signaling effectors of EGFR, 
such as farnesyl transferase inhibitors, angiogenesis inhibitors, 
and the multikinase inhibitor sorafenib.
Both mAbs and TKIs designed to block EGFR signaling 
have been extensively studied in a variety of malignancies, 
including pancreatic cancer. While the clinical focus of these 
agents has been on solid tumors with high levels of EGFR 
expression whose malignant phenotypes are known to be 
dependent on EGFR signaling, EGFR expression in and of 
itself may not be a reliable indicator of the potential antitumor 
activity of either class of agents, as will be discussed later. 
Moreover, although mAbs and TKIs may putatively have 
the same primary target, their activity proﬁ  les may in fact 
be quite different. TKIs have the advantage of being orally 
bioavailable and are more rapidly distributed throughout the 
body than mAbs; on the other hand, they may be less speciﬁ  c 
for their target than mAbs, and exhibit dose-limiting toxicities 
not generally observed with antibody therapy (Mendelsohn 
and Baselga 2003).
Cetuximab (Erbitux®, Imclone/Bristol-Meyers Squibb, 
New York), is a chimeric anti-EGFR mAb now approved 
for use in both head and neck and advanced colorectal can-
cers. The fully humanized anti-EGFR mAb panitumumab 
(Vectibix®, Amgen, Thousand Oaks, CA, USA) has also 
recently received approval in the salvage setting for advanced 
colorectal cancer. Other anti-EGFR mAbs under investiga-
tion include matuzumab and nimotuzumab (Cohenuram and 
Saif 2007). Evidence of promising activity of cetuximab in 
pancreatic cancer led to a large phase III study conducted by 
the Southwest Oncology Group (S0205), in which patients 
with locally advanced or metastatic pancreatic cancer were 
randomized to receive gemcitabine alone or in combination 
with cetuximab (Philip et al 2007). However, this 735-patient 
study showed no signiﬁ  cant difference in median survival, 
progression-free survival (PFS), or response rate in patients 
on the cetuximab-containing arm.
The TKI erlotinib was ﬁ  rst approved for use in 2004 
in patients with advanced or metastatic NSCLC who had 
progressed on a platinum-based chemotherapy regimen. 
Another TKI, geﬁ  tinib (ZD1839, Iressa®; AstraZeneca, 
Wilmington, DE, USA), was also originally approved for 
advanced NSCLC, but its use has since been restricted to 
patients who had achieved documented clinical benefit 
from this agent or who were enrolled in selected clinical 
trials. More recently, lapatinib (Tykerb®, GlaxoSmithKline, 
Philadelphia, PA, USA), an oral TKI directed against both 
EGFR and the associated HER family member HER-2, has 
been approved for use in women with advanced HER-2 (+) 
breast cancer.
As noted above, the FDA approved erlotinib for use in 
pancreatic cancer in 2005. The remainder of this review will Biologics: Targets & Therapy 2008:2(1) 86
Kelley and Ko
discuss the preclinical and clinical data supporting a role for 
targeted anti-EGFR therapy in advanced pancreatic cancer, 
with speciﬁ  c attention to this particular agent.
Rationale for EGFR as a therapeutic 
target in pancreatic cancer
In the normal pancreas, EGFR expression is limited to ductal 
cells and the islets of Langerhans (Ueda et al 2004). Similar 
to a number of other malignancies, EGFR has been shown 
to be overexpressed in pancreatic cancers (Yamanaka et al 
1993; Arteaga 2001; Tobita et al 2003; Grandis and Sok 
2004; Marshall 2006). EGFR overexpression with resultant 
increase in EGFR signaling may be associated with metastatic 
potential and decreased survival in patients with pancreatic 
cancer. Tobita et al studied EGFR expression by immunohis-
tochemistry in 77 cases of invasive ductal adenocarcinoma of 
the pancreas and found EGFR expression to be signiﬁ  cantly 
associated with metastatic potential (Tobita et al 2003). 
Likewise, Ueda et al demonstrated that cytoplasmic EGFR 
overexpression by immunohistochemistry was associated 
with higher grade tumors and shorter survival in a study 
of 76 archived cases of pancreatic ductal carcinoma (Ueda 
et al 2004). In contrast, membranous EGFR staining did not 
correlate with tumor grade or survival in a study of 71 cases 
of pancreatic adenocarcinoma by Bloomston et al (2006).
In addition to overexpression of EGFR, autocrine stimula-
tion of the receptor may also play a role in the pathogenesis 
of pancreatic cancer. In a pancreatic tumor cell line, Murphy 
et al showed that autocrine stimulation of EGFR in vitro 
results in sustained cell proliferation that can be abrogated 
by inhibiting EGFR tyrosine kinase activity, by administering 
inhibitors of downstream MAPK signaling, or by frequently 
changing the culture medium to remove potential autocrine 
growth factors (Murphy et al 2001).
Though EGFR activating mutations have been dem-
onstrated in certain malignancies including NSCLC and 
gliomas, similar mutations have not been identiﬁ  ed in pancre-
atic cancer to date. The EGFR sequence appears to be highly 
conserved in pancreatic cancer (Lee et al 2007; Tzeng et al 
2007a). A deletion in exon 19 was identiﬁ  ed in 3.6% (2 of 
55) patients with pancreatic cancer in a study by Kwak et al 
although the small sample size precluded interpretation of 
the clinical signiﬁ  cance of this ﬁ  nding (Kwak et al 2006). 
In another small study of 30 pancreatic surgical specimens 
and 9 pancreatic cancer cell lines, investigators identiﬁ  ed a 
polymorphism in EGFR intron 1 that was associated with 
shorter survival (Tzeng et al 2007b). Though hypothesized to 
increase transcriptional efﬁ  ciency of EGFR and thus lead to 
overexpression, the polymorphism was not associated with 
any increased expression of downstream molecular markers 
of EGFR pathway activation.
At this time, the mechanism of EGFR activation in pan-
creatic cancer remains poorly understood. Gene ampliﬁ  ca-
tion, autocrine or paracrine upregulation, altered receptor 
processing, ligand overexpression, and/or dysregulation of 
co-receptor dimerization each may represent a potential con-
tributing factor. Despite the current gaps in our knowledge, 
the evidence of EGFR overexpression in pancreatic cancer 
specimens, combined with convincing in vitro data demon-
strating the oncogenic potential of EGFR activation, together 
support a role for EGFR activation in the progression of this 
malignancy. Preclinical and clinical data of pharmacologic 
EGFR inhibition in pancreatic cancer further support this 
principle and are presented below.
Preclinical data of EGFR inhibition 
by TKIs in pancreatic cancer
Preclinical studies in a variety of solid tumor cell lines have 
demonstrated anti-tumor effect of EGFR inhibition by TKIs, 
including several studies speciﬁ  c to pancreatic cancer. In two 
pancreatic cancer mouse xenograft models, erlotinib alone 
and in combination with gemcitabine signiﬁ  cantly inhibited 
EGFR phosphorylation and increased apoptosis (Ng et al 
2002). Treatment of the human pancreatic cell line HPAC 
with erlotinib reduced cell proliferation in tissue culture 
(Durkin et al 2006). When these HPAC cells were implanted 
into athymic/nude mice, the tumors that formed both grew 
more slowly and exhibited decreased metastatic potential 
when the mice were treated with erlotinib. A separate study 
showed that the TKI geﬁ  tinib completely inhibited EGF-
induced cell proliferation as well as EGFR autophosphoryla-
tion and phosphorylation of MAPK in pancreatic cancer cell 
lines (Li et al 2004). PKI-166, another TKI in development, 
was shown to have activity alone and in combination with 
gemcitabine in a mouse xenograft model of pancreatic cancer 
(Bruns et al 2000).
Erlotinib is a low molecular weight quinazolin derivative 
which acts to selectively and reversibly inhibit of EGFR 
tyrosine kinase activity (Grunwald and Hidalgo 2003; Pao 
and Miller 2005). Molecular studies show that erlotinib selec-
tively inhibits EGFR tyrosine kinase activity at concentrations 
of 2nM in puriﬁ  ed assays and 20nM in whole-cell assays; 
nonspeciﬁ  c inhibition of unrelated tyrosine kinases occurs 
at 1000-fold higher concentrations (Grunwald and Hidalgo 
2003). In pharmacokinetic analyses using the head and neck 
tumor cell line HN5, maximum inhibitory effects as measured Biologics: Targets & Therapy 2008:2(1) 87
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by EGFR-associated phosphotyrosine and tumor growth were 
obtained 1 hour post treatment with erlotinib, with 75%–85% 
inhibition maintained for at least 12 hours; recovery to base-
line activity occurred by 24 hours (Pollack et al 1999). Based 
on preclinical animal data, human plasma concentrations of 
0.5 μg/mL have been estimated to inhibit EGFR adequately 
to achieve antitumor effect (Hidalgo et al 2001). A direct 
relationship exists between degree of EGFR inhibition and 
antitumor effect, suggesting the need for adequate dosing 
(Grunwald and Hidalgo 2003; Marshall 2006).
Clinical trials of erlotinib 
in pancreatic cancer
Based on the above preclinical ﬁ  ndings, erlotinib has under-
gone extensive evaluation in numerous clinical trials and has 
gained approval for use in both NSCLC and pancreatic caric-
noma. The original phase I trials of this agent were conducted 
in previously treated patients with a broad range of solid 
tumors and allowed for the establishment of optimal dosing 
and toxicity proﬁ  les. In one such study, Hidalgo et al evalu-
ated erlotinib as a single agent in 40 patients with advanced 
solid malignancies in doses ranging from 25 to 200 mg daily, 
in continuous and intermittent schedules, and established 
a maximum tolerated daily dose of 150 mg (Hidalgo et al 
2001). 59% of patients (23/39) on study developed grade 1-2 
dermatologic toxicity, including 41% (9/22) at the 150 mg 
once-daily dosing schedule. Although no grade 3-4 dermato-
logic toxicity was reported, 3 patients, including 1 at the 150 
mg daily dosing, required termination of treatment because 
of clinically intolerable rash. Rash and diarrhea were the 
dose-limiting toxicities at doses higher than 150 mg. Other 
principal toxicities included mucositis, hyperbilirubinemia, 
and headache. Pharmacokinetic analysis indicated that a dose 
of 150 mg daily produced plasma concentrations greater 
than 0.5 μg/mL in most patients, corresponding to the level 
expected to result in antitumor activity from the preclinical 
studies described above.
A phase I study initially presented at the 2004 annual 
meeting of the American Society of Clinical Oncology 
(ASCO), since published, evaluated escalating doses of 
erlotinib in combination with standard-dose gemcitabine 
(1000 mg/m2 weekly x 7, then weekly x 3 every 4 weeks) in 
26 patients, the majority (n = 15) of whom had pancreatic 
cancer (Porterﬁ  eld et al 2004; Dragovich et al 2007). Two 
sequential cohorts were enrolled, the ﬁ  rst cohort receiving 
erlotinib at 100 mg daily and the second 150 mg daily. 
Because 3 of 9 patients at the 100 mg dose level developed 
grade 3 transaminitis, the study protocol was subsequently 
amended to increase the stringency of entry criteria, limiting 
patients to no more than one prior chemotherapy regimen, 
transaminases less than 1.5× upper limits of normal, and 
a bilirubin within normal range. The most common non-
hematologic toxicity was skin rash, occurring in 18 of 26 
patients (69%), none higher than grade 2. Incidence of skin 
rash was similar at the 100 mg and 150 mg dose levels (67% 
and 71%, respectively). Other common toxicities included 
diarrhea in 14 patients (54%), 3 of whom had grade 3; nausea 
in 11 patients (42%), one of whom had grade 3; and fatigue 
in 14 patients (54%), 4 of whom had grade 3. Four patients 
(15%) also developed grade 3 neutropenia. There was 1 
fatal episode of pulmonary toxicity in a patient with NSCLC 
previously treated with chemoradiation. On the whole, the 
toxicity proﬁ  le of this combination appeared acceptable, 
with patients able to tolerate gemcitabine plus erlotinib at 
150 mg daily with manageable side effects. Moreover, of the 
12 patients with pancreatic cancer evaluable for response, 
1 had a partial response (8%), and 9 had stable disease for 
more than 3 months (75%).
The pivotal study upon which the FDA approval of 
erlotinib for use in pancreatic cancer was based was PA.3, 
a phase III trial conducted by the National Cancer Institute 
of Canada Clinical Trials Group (NCIC-CTG). Results of 
this study were ﬁ  rst presented at the ASCO Gastrointestinal 
Cancers Symposium in 2005 and have since been recently 
published (Moore et al 2007b). PA.3 compared gemcitabine 
plus erlotinib with gemcitabine plus placebo as ﬁ  rst-line 
therapy in patients with advanced pancreatic cancer. The 
study was a randomized, double-blind, placebo-controlled 
international trial with 176 centers in 17 countries. Enroll-
ment consisted of 569 patients with locally advanced or 
metastatic adenocarcinoma of the pancreas, measurable 
disease, and an ECOG performance status (PS) between 0 
and 2. Prior radiotherapy for local disease was allowed with 
ﬂ  uorouracil or gemcitabine given concurrently as a radiosen-
sitizer; patients could not have been previously treated with 
chemotherapy for advanced disease. Appropriate stratiﬁ  ca-
tions were made for both PS and disease stage; approximately 
80% of patients on each arm had an ECOG PS of 0 or 1, and 
75% had metastatic disease. Of note, EGFR overexpression 
was not required for enrollment.
All patients received gemcitabine 1000 mg/m2 by 
30-minute infusion weekly for 7 weeks followed by 1 week 
rest in cycle 1. Subsequent cycles were administered weekly 
for 3 weeks followed by 1 week rest. Patients were randomized 
to receive erlotinib (285 patients) or placebo (284 patients). 
The vast majority of patients on the study arm received Biologics: Targets & Therapy 2008:2(1) 88
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erlotinib at a dose of 100 mg daily until disease progression or 
unmanageable toxicity. During the latter portion of the study, 
a small Canadian cohort of 48 patients received erlotinib at 
150 mg daily to assess the tolerability of this higher dose.
The PA.3 study was powered for overall survival as the pri-
mary endpoint. Secondary endpoints included PFS, response 
rate, response duration, toxicity, quality of life (QOL), and 
correlation of tumor EGFR expression with clinical outcome. 
Analysis of results showed median survival in patients 
randomized to gemcitabine plus erlotinib was 6.24 months 
as opposed to 5.91 months in the gemcitabine plus placebo 
group; one year survival was 23% versus 17%, respectively 
(p = 0.23). The hazard ratio (HR) for overall survival was 
0.82 (p = 0.038). PFS was also signiﬁ  cantly improved in the 
erlotinib arm (3.75 months) as compared with the placebo arm 
(3.55 months) with HR of 0.77 for progression (p = 0.004). 
Response rates were not signiﬁ  cantly different between treat-
ment groups (8.6% versus 8.0%), although a trend towards 
improved rate of disease control was observed for patients in 
the erlotinib arm (57.5% versus 49.2%, p = 0.07). There was 
no difference in response duration between groups. Figure 1 
depicts Kaplan-Meier curves for overall survival and progres-
sion-free survival in the PA.3 study.
Toxicity analysis showed treatment to be well-tolerated 
in both treatment groups. Patients in the erlotinib arm had 
higher incidence of rash, diarrhea, infection, and stomatitis. 
Skin rash was the most common toxicity, occurring in 203 of 
282 of patients (72%) on the erlotinib-containing arm, fully 
half (36%) of whom were categorized as having grade 2 or 
higher. The incidence of grade 3-4 rash was 6% versus 1% 
in the erlotinib versus placebo arms, respectively.
As for non-dermatologic toxicity, the incidence of grade 
3-4 diarrhea was 6% versus 2%. No differences in grade 3-4 
hematologic toxicity were observed between the two arms. 
Of note, the incidence of interstitial lung disease (ILD) 
syndromes was 2.1% in the erlotinib arm versus 0.4% in 
the placebo arm. For comparison, the incidence of ILD was 
reported to be less than 1% in the Tarceva Lung Cancer Eval-
uation Trial (TALENT) which evaluated gemcitabine plus 
cisplatin with or without erlotinib in patients with advanced 
lung cancer (Gatzemeier et al 2007). In the PA.3 study, 
there were 6 protocol-related deaths overall, all of which 
occurred in the erlotinib arm. Two deaths were attributed 
to treatment complications (ILD and sepsis), while 4 were 
attributed to cancer complications combined with possible 
treatment-related effects.
Dose reductions for toxicity were required in 16% of 
patients in the erlotinib arm as opposed to 5% in the 
placebo arm. Dose reductions were more common in the 
small cohort of patients receiving the higher 150 mg dose 
of erlotinib (48% of patients at this level required a dose 
reduction) compared to those receiving a dose of 100 mg 
daily (dose reduction required in 13%).
Despite these differences in toxicity proﬁ  les, there was 
no difference in global QOL scores using the European 
Organisation for Research and Treatment of Cancer Core 
Quality of Life Questionaire C30 (EORTC QLQ-C30) 
instrument. Individual domain scores were also equivalent 
with the exception of diarrhea which was reported as worse 
in the erlotinib arm (p  0.001). Of note, the EORTC 
QLQ-C30 instrument does not speciﬁ  cally address qual-
ity of life issues relating to skin toxicity. Given that even 
mild-to-moderate rash can confer impairment and distress, 
its effects on quality of life may be signiﬁ  cant (Gridelli 
et al 2007).
The PA.3 study also assessed EGFR expression in 162 
tumor samples adequate for immunohistochemical EGFR 
Figure 1 Kaplan-Meier curves for (A) overall survival; and (B) progression-free 
survival. HR = hazard ratio. Reproduced with permission from Moore MJ, Goldstein 
D, Hamm J, et al 2007b. Erlotinib plus gemictabine compared to gemcitabine alone 
in patients with advanced pancreatic cancer: a phase III trial of the National Cancer 
Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960-6. Copyright © 2007. 
American Society of Clinical Oncology.
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analysis. Of these tumors, 86 (53%) were EGFR positive 
(as deﬁ  ned by at least 10% of cells staining positive) and 76 
(47%) were EGFR negative. EGFR status was not signiﬁ  -
cantly associated with response to erlotinib. Interestingly, 
subgroup analysis was notable for skin rash being associated 
with disease control with erlotinib (p = 0.05). Median survival 
for patients with grade 0, 1, and 2+ rash were 5.3, 5.8, and 
10.5 months, respectively, with 1-year survival rates of 16%, 
9%, and 43% (p  0.001) (Figure 2).
In conclusion, the PA.3 study showed that erlotinib 
in combination with gemcitabine results in a statistically 
signiﬁ  cant improvement in overall survival in patients with 
advanced pancreatic cancer in the ﬁ  rst-line setting. Although 
the absolute beneﬁ  t in overall survival was modest with a 
median survival difference between the two arms of only 
2 weeks, the hazard ratio of 0.82 corresponds to a 22% 
improvement in survival overall (Moore et al 2007b). The 
hazard ratio may represent a more clinically meaningful 
parameter in a rapidly-progressive disease like pancreatic 
cancer in that it measures risk over a time continuum and may 
better reﬂ  ect differences in survival than a static time point 
such as the median. Ultimately, the PA.3 study represents 
the ﬁ  rst phase III study to demonstrate a survival beneﬁ  t 
of combination therapy over gemcitabine monotherapy in 
advanced pancreatic cancer.
A number of questions arise in evaluating the results 
of this trial. The high incidence of ILD in the erlotinib arm 
is noteworthy, particularly by comparison to the lower 
incidence seen in TALENT which also used erlotinib in 
combination with gemcitabine. This ﬁ  nding raises the possi-
bility of an additive toxicity with these agents in combination. 
Also worth pointing out are the subgroup analysis ﬁ  ndings 
identifying female gender as being signiﬁ  cantly associated 
with longer overall survival. This is particularly relevant 
given the gender imbalance between treatment arms (52.3% 
females in the erlotinib arm compared to 43.0% in the pla-
cebo arm). The authors report that treatment effect remained 
signiﬁ  cant when adjusted for sex, but these data were not 
presented. The optimal dose of erlotinib in this study also 
remains in question; the authors recommend a starting dose 
of 100 mg daily with consideration of dose escalation to 
150 mg daily as tolerated. Dose reductions for toxicity in 
the 150 mg group greatly exceeded those in the 100 mg 
group, however, suggesting that dose escalations must be 
undertaken with caution.
Most importantly, the question remains how to identify 
patients who will beneﬁ  t from the addition of erlotinib. 
Although there was no relationship between clinical outcome 
and EGFR expression by immunohistochemistry, subgroup 
analysis in the PA.3 study did identify the development of 
rash as a signiﬁ  cant predictor of response, a ﬁ  nding that has 
been observed in studies evaluating other EGFR inhibitors in 
other tumor types. This subject will be discussed in further 
detail in a subsequent section.
In addition to PA.3, smaller studies have evaluated 
erlotinib in other settings and combinations for advanced 
pancreatic cancer. A phase II study presented at the annual 
meeting of ASCO in 2005 evaluated the combination of 
capecitabine and erlotinib as a second-line regimen in 28 
patients with metastatic pancreatic cancer after failure of 
front line therapy with gemcitabine (Blaszkowsky et al 2005). 
This study reported a well-tolerated toxicity proﬁ  le as well 
as a promising median survival of 6.7 months. Three patients 
(11%) were assessed as having a partial response and an 
additional 16 (57%) demonstrated stable disease. Another 
phase II study presented at the annual meeting of ASCO 
in 2006 randomized 58 previously untreated patients with 
advanced pancreatic cancer to treatment arms consisting of 
bevacizumab (B) and gemcitabine (C) plus either erlotinib (E) 
or cetuximab (C) (Kindler et al 2006). Preliminary analysis 
suggested activity of both regimens (GBE and GBC) with 
overall responses of 21% and 19%, respectively; similar 
six-month survival rates (38% and 41%); and minimal differ-
ences in toxicity proﬁ  les. A separate phase I study of erlotinib 
and gemcitabine in combination with bevacizumab is now 
underway (Gomez-Martin et al 2007). Erlotinib may also 
have very modest activity as a single agent or in combina-
tion with bevacizumab for patients who have progressed on 
prior chemotherapy (Epelbaum et al 2007; Ko et al 2007). 
Figure 2 Overall survival by grade of rash in patients treated with erlotinib in PA.3 study. 
Reproduced with permission from Moore MJ, Goldstein D, Hamm J, et al 2007b. Erlotinib 
plus gemictabine compared to gemcitabine alone in patients with advanced pancreatic 
cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. 
J Clin Oncol, 25:1960-6. Copyright © 2007.   American Society of Clinical Oncology.
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Clinical trials of erlotinib in advanced pancreatic cancer are 
reviewed in Table 1.
Predicting response to EGFR 
inhibition
Studies in a variety of solid tumor types have evaluated 
EGFR expression by immunohistochemical staining and 
have found equivocal association with clinical outcome 
in response to EGFR inhibition. A potential limitation of 
immunohistochemistry (IHC) in the assessment of EGFR 
expression is the uncertain recognition of truncated or 
mutated receptors, or receptors that have been internalized 
to the cytoplasm. Furthermore, EGFR expression may be 
differentially predictive in particular subsets of cases, leading 
to confounding results in population studies. In colorectal 
cancer, EGFR staining does not appear to correlate with clini-
cal response to cetuximab; moreover, patients with negative 
immunohistochemical staining for EGFR have demonstrated 
responses to cetuximab (Cunningham et al 2004; Chung et al 
2005). In NSCLC patients, EGFR expression by IHC was 
not associated with response to geﬁ  tinib in the Iressa Dose 
Evaluation in Advanced Lung Cancer (IDEAL) trials (Bell 
et al 2005; Marshall 2006). Conversely, pooled data from 
two randomized, placebo-controlled trials in NSCLC, SWOG 
0126 and an Italian study by Cappuzzo et al showed EGFR 
IHC to be an independent predictive marker of response to 
geﬁ  tinib (Cappuzzo et al 2005; Hirsch et al 2007). Limited 
data from a phase II study of erlotinib in head and neck can-
cers did not ﬁ  nd EGFR staining by IHC to be predictive of 
response (Soulieres et al 2004). In pancreatic cancer, EGFR 
expression by immunohistochemistry likewise has not been 
shown to correlate with clinical response. In the PA.3 study 
discussed above, there was no differential response to therapy 
in the EGFR positive and EGFR negative subgroups with 
hazard ratios of 0.80 and 0.83, respectively (Moore et al 
2007b). At this time, there is no data to support the decision 
to use EGFR inhibitor therapy based on EGFR expression 
by IHC alone.
FISH and PCR analysis have also been used to evaluate 
tumor specimens for EGFR gene ampliﬁ  cation and presumed 
resulting overexpression. In NSCLC, increased EGFR copy 
number appears to correlate with response to the TKI geﬁ  tinib 
(Bell et al 2005; Hirsch et al 2005; Pao and Miller 2005; 
Takano et al 2005; Shepherd and Tsao 2006; Cappuzzo 
et al 2007; Hirsch et al 2007). It is not known, however, 
whether gene ampliﬁ  cation alone or in concert with an 
accompanying EGFR mutation confers increased response 
to TKI therapy. In a study of 66 pancreatic tumor specimens, 
increased EGFR copy numbers were detected by PCR in 41% 
of tumors (26/66); no association was found between copy 
Table 1 Clinical trials of erlotinib in advanced pancreatic cancer
Reference Type of trial No. of patients Prior treatments Regimen Erlotinib dose/
day
Activity
Porterﬁ  eld 2005 Phase I 14 No prior G G + E 100–150 mg PR 7% MR 21% 
SD 42%
Moore 2007 Phase III 569 No prior chemo-
therapya
Randomized G + E 
or G + P
100–150 mg G + E arm: CR + 
PR 8.6% SD 48.9% 
OS 6.24 mo. PFS 
3.75 mo.
Blaszkowsky 2005 Phase II 28 Failed G CAPE + E 150 mg PR 11% SD 57% 
MS 6.7 mo.
Kindler 2006 Phase II 58 No prior chemo-
therapy
Randomized GBE 
or GBC
150 mg GBE arm: PR 21% 
SD 67% PFS 3.6 mo.
Gomez-Martin 
2007b
Phase I 12 NR E + B + Gc 150 mg Incomplete data
Epelbaum 2007 Phase I 13 Failed  1 prior 
chemotherapy
E 150 mg CI 23% SD 15%
Ko 2007 Phase II 25 Failed 1–3 prior 
chemotherapies
E + B 150 mg PR 4% SD 28%
aExcept ﬂ  uorouracil or gemcitabine as radiosensitizer.
bPhase I study ongoing.
cGemcitabine doses 850 mg/m2 or 1000 mg/m2.
Abbreviations: G, gemcitabine; E, erlotinib; PR, partial response; MR, minor response; SD, stable disease; P, placebo; CR, complete response; PFS, progression free survival; 
CAPE, capecitabine; MS, median survival; GBE, gemcitabine, bevacizumab, and erlotinib; GBC, gemcitabine, bevacizumab, and cetuximab; NR, not reported; CI, clinical 
improvement.Biologics: Targets & Therapy 2008:2(1) 91
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number and survival (Lee et al 2007). In another study of 55 
pancreatic tumor specimens, no ampliﬁ  cation of EGFR by 
PCR was found in ﬁ  ve cases that had demonstrated response 
to therapy with capecitabine plus erlotinib (Kwak et al 2006). 
In the PA.3 study, relationship of EGFR gene copy number 
to outcome was analyzed in a subset of 107 patients in whom 
tumor tissue was available. FISH-positivity for EGFR (46.7% 
of samples) was found to be a negative prognostic factor for 
progression-free survival irrespective of treatment (HR 1.85, 
p = 0.004) (Moore et al 2007a). Moreover, the hazard ratio 
showed a trend toward greater beneﬁ  t of erlotinib in patients 
who were EGFR FISH negative (HR 0.60, p = 0.08), although 
the authors concede that the sample size was too small to 
draw any ﬁ  rm conclusions.
Recent studies in NSCLC have also identiﬁ  ed somatic 
mutations within the EGFR gene that are strongly associated 
with response to gefitinib or erlotinib. Retrospective 
studies collectively show that over 80% of NSCLC patients 
who demonstrated clinical response to either geﬁ  tinib or 
erlotinib harbored a mutation within the EGFR tyrosine 
kinase domain (Paez et al 2004; Lynch et al 2004; Pao 
and Miller 2005, Takano et al 2005). By comparison, the 
IDEAL trials identiﬁ  ed EGFR gene mutations in only 50% 
of responders, but nonetheless corroborated a signiﬁ  cant 
difference in response to geﬁ  tinib therapy in those patients 
with EGFR mutations (46%) compared to those without 
(10%) (p = 0.005) (Bell et al 2005). In the phase III INTACT 
trial, however, there was no survival beneﬁ  t identiﬁ  ed with 
the addition of geﬁ  tinib to chemotherapy in NSCLC patients 
with EGFR gene mutations (Bell et al 2005). Interpretation 
of these ﬁ  ndings is complicated by the recognition that 
EGFR gene mutation and ampliﬁ  cation are prognostic 
as well as predictive factors in NSCLC (Shepherd and 
Tsao 2006).
In pancreatic cancer, preclinical studies suggest EGFR 
mutations are infrequent, making it difﬁ  cult to assess their 
association with responsiveness to anti-EGFR therapy (Kwak 
et al 2006; Lee et al 2007; Tzeng et al 2007a). As noted 
previously, an intron 1 polymorphism with variable length 
of CA repeats was recently characterized in a study of 30 
microdissected pancreatic surgical specimens and 9 cell 
lines (Tzeng et al 2007b). A shorter sum of CA repeats (less 
than 36) was associated with shorter median survival than in 
patients with greater than or equal to 36 repeats. Additionally, 
cell lines with a shorter intron 1 length demonstrated an in 
vitro response to erlotinib (p = 0.02). To date, EGFR intron 
1 CA repeat length has yet to be conﬁ  rmed as a prognostic 
or predictive factor in clinical trials.
Another potential molecular predictor of response to 
therapeutic EGFR inhibition is the presence or absence of 
mutant K-ras. RAS/MAP kinase represents one of the down-
stream effector pathways of EGFR signaling, and mutations 
in any of these signaling components could lead to resistance 
to therapeutic agents such as erlotinib (Eberhard et al 2005). 
Analysis of a subset of NSCLC patients on the TRIBUTE 
trial of chemotherapy with or without erlotinib demonstrated 
signiﬁ  cantly decreased time to tumor progression and overall 
survival in those individuals with an activating K-ras mutation 
(21% of the evaluable cohort) on the erlotinib-containing arm 
(Eberhard et al 2005). Given the very high frequency of K-ras 
mutations seen in pancreatic cancer, one might similarly ask 
whether such mutations affect response to erlotinib in this 
patient population. Moore and colleagues were able to assess 
the K-ras mutational status in a subset of 117 patients on the 
PA.3 trial (Moore et al 2007a), 92 (78.6%) of whom had 
mutated K-ras. While a trend toward greater beneﬁ  t of erlotinib 
for overall survival was observed in patients with wild-type 
K-ras (HR 0.66), this ﬁ  nding was not statistically signiﬁ  cant 
(p = 0.34). A prospective study that is adequately powered to 
answer this question more precisely is necessary.
In terms of clinical predictors of response, the devel-
opment of skin rash has been suggested as a surrogate 
marker of favorable response to EGFR inhibition by both 
TKI and MAb across a variety of solid tumor types. The 
characteristic EGFR inhibitor rash is papulopustular, occur-
ring predominantly on the face and upper torso within 
two weeks of the start of treatment. Although the etiology 
remains unclear, the rash is postulated to occur secondary 
to EGFR inhibition in the skin (Perez-Soler and Saltz 2005). 
The overall incidence of rash with EGFR inhibitor therapy 
ranges from 50% to 100%, depending on the type of can-
cer, dose, and the speciﬁ  c EGFR inhibitor used. A much 
smaller percentage of patients experience grade 3 or 4 rash, 
characterized by a generalized, symptomatic dermatitis 
covering greater than 50% of body surface area (Segaert 
and Van Cutsem 2005). In colorectal cancer, response 
rates to cetuximab were shown to be signiﬁ  cantly higher 
in patients with adverse skin reactions in several studies 
(Cunningham et al 2004; Lenz et al 2005). Multiple studies 
of both TKI and MAb in NSCLC, head and neck cancer, 
and ovarian cancer also suggest that development of rash 
is associated with improved outcomes (Wacker et al 2007). 
In pancreatic cancer, the PA.3 study corroborated these 
ﬁ  ndings, showing that the presence of rash correlated with 
improved outcomes as discussed in the previous section 
(Moore et al 2007b) (Figure 2).Biologics: Targets & Therapy 2008:2(1) 92
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The mechanism of association between rash and 
improved outcome in EGFR inhibition remains unclear. 
The rash may reflect individual differences in drug 
exposure due to metabolism, differences in the immune 
system, or EGFR polymorphisms (Wacker et al 2007). 
A potential confounding variable is the duration of time 
on therapy, which is longer in patients with response to 
therapy and may result in a higher incidence of skin rash 
independent of any true surrogacy for outcome. Like-
wise, nonresponders with poor outcome may become 
too ill and discontinue therapy prior to development or 
documentation of rash, leading to underreporting of rash 
in this subset of patients. To address this confounding 
variable, a combined analysis was conducted of the phase 
III NCIC-CTG studies BR.21 of erlotinib monotherapy 
in advanced NSCLC and PA.3 in pancreatic cancer. This 
study excluded patients who died within the ﬁ  rst month on 
study to minimize the potential bias created by early deaths. 
The combined analysis showed that the presence of rash 
strongly correlated with overall survival in both studies, 
corroborating previous data (Wacker et al 2007). If skin rash 
is a true surrogate for the degree of EGFR inhibition within 
the tumor, the question arises whether the dosage of EGFR 
inhibitors should be escalated to the development of this rash 
if tolerated without signiﬁ  cant other toxicities.
Future directions for EGFR 
inhibitor therapy in pancreatic 
cancer
The challenge remains how to identify the subset of advanced 
pancreatic cancer patients most likely to beneﬁ  t from EGFR 
inhibition. In breast cancer, Her2 status by immunohisto-
chemistry and FISH predicts response to trastuzumab, the 
monoclonal antibody to Her2 which, like EGFR, is a mem-
ber of the HER family of receptors. In NSCLC, a subset 
of patients demonstrates a strong, durable response to TKI 
therapy. Multiple studies suggest that EGFR gene ampliﬁ  -
cation and EGFR mutations are associated with response in 
these patients, leading to the promise of applying a targeted 
therapy primarily to those individuals most likely to beneﬁ  t, 
especially in a disease in which short survival time renders 
ineffectual therapy particularly costly. As discussed above, 
molecular markers predictive of response have not yet been 
identiﬁ  ed among pancreatic cancer patients. Further study is 
required to evaluate biomarkers that may play a predictive 
or prognostic role in this aggressive malignancy.
Optimal dosing of erlotinib in advanced pancreatic cancer 
patients also remains in question. In the PA.3 trial, a dose of 
150 mg daily was associated with signiﬁ  cantly higher toxicity 
than 100 mg daily and required dose reductions in 48% of 
patients (Moore et al 2007b). In vitro studies suggest that drug 
concentration directly correlates with degree of antitumor 
effect, however, underscoring the importance of adequate dos-
ing. Furthermore, the incidence of rash is greater with higher 
doses of EGFR inhibitor (Segaert and Van Cutsem 2005). In 
concert with data suggesting that rash may be a biomarker for 
tumor response to EGFR inhibition, this dose-toxicity relation-
ship suggests the need for future study of dose escalation to 
the development of rash, similar to studies being conducted 
with cetuximab in colorectal cancer (Tejpar et al 2007). It is 
unknown whether higher doses of erlotinib can induce rash in 
a greater proportion of patients, and whether this would result 
in improved clinical outcomes without unacceptable toxic-
ity. Given that even mild-to-moderate skin rash can result in 
signiﬁ  cant patient distress and impairment, the clinical beneﬁ  t 
of anti-EGFR therapy must be carefully weighed against the 
toxicity of this common side effect.
The positive results of the PA.3 trial introduce multiple 
potential new applications for the TKI erlotinib in pancreatic 
cancer. In the adjuvant setting, a recent phase III study demon-
strated a signiﬁ  cant beneﬁ  t in disease free survival with the use 
of postoperative gemcitabine in resectable pancreatic cancer 
(Oettle et al 2007). These results together with the results of 
the PA.3 study raise the possibility of a beneﬁ  t from erlotinib 
in combination with cytotoxic chemotherapy in the resectable 
population as well, although obviously one must apply caution 
before extrapolating positive results in patients with advanced 
cancer to those with earlier stages of disease.
Further study may also identify potential additive or 
synergistic effects of erlotinib in combination with other 
chemotherapeutic or biologic agents, as inhibition of EGFR 
signaling by TKI or MAb theoretically may sensitize tumor 
cells to non-speciﬁ  c cellular stresses and augment the efﬁ  -
cacy of other therapies. Another avenue for investigation is 
the evaluation of erlotinib as a radiosensitizer. It has been 
previously demonstrated that EGFR activation contributes to 
radiation resistance (Schmidt-Ullrich et al 1997; Dent et al 
1999), and in preclinical models, this enhanced tumor-cell 
survival and radiation resistance may be overcome by inhi-
bition of EGFR (Huang et al 1999; Lammering et al 2001; 
Krishnan et al 2006). A recent phase I study of erlotinib in 
combination with twice weekly gemcitabine and radiation 
therapy for locally advanced pancreatic cancer showed this 
combination to be well-tolerated with promising efﬁ  cacy, 
reporting a partial response rate of 35% and stable disease 
rate of 53% in 17 assessable patients (Duffy et al 2008). Biologics: Targets & Therapy 2008:2(1) 93
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Other ongoing studies in resected and locally advanced 
pancreatic cancer are evaluating erlotinib together with 
other chemotherapy platforms, such as capecitabine ± 
gemcitabine and gemcitabine plus oxaliplatin concurrent 
with radiation.
In conclusion, the PA.3 study has provided important 
proof of principle for the role of EGFR tyrosine kinase 
inhibition in advanced pancreatic cancer. Despite small 
differences in overall survival, the addition of erlotinib to 
gemcitabine produced a signiﬁ  cant difference in hazard ratio 
for survival in this rapidly progressive malignancy and now 
represents an appropriate standard of care option for patients. 
Given these ﬁ  ndings in the context of the preclinical and 
clinical data presented above, ongoing study is warranted to 
better characterize the potential beneﬁ  ts of EGFR inhibition 
as a valuable therapeutic strategy in pancreatic cancer.
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